Owner foundation to sell Leo Pharma stake

The foundation behind Leo Pharma plans to divest parts of the Danish pharmaceutical company, in part to secure Leo Pharma’s options in realizing a new 2030 strategy. The foundation’s CEO keeps options open – even going on the stock exchange.

Photo: Leo Pharma / PR

Denmark’s third-largest pharmaceutical company, Leo Pharma, might have some new owners to get used to.

The current owner, Leo Foundation, intends to sell parts of the firm’s shares, partially in order to finance the pharmaceutical company’s 2030 strategy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Latest news

See all jobs